These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21752914)

  • 1. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
    Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
    J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
    Mandal D; Exline CM; Feng Z; Stoltzfus CM
    J Virol; 2009 Jun; 83(12):6067-78. PubMed ID: 19357165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
    Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
    Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
    Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
    Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
    Britan-Rosich E; Nowarski R; Kotler M
    J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
    Green LA; Liu Y; He JJ
    J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
    Hosseini I; Mac Gabhann F
    PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
    Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M
    Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
    Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
    Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo.
    De Pasquale M; Kourteva Y; Allos T; D'Aquila RT
    PLoS One; 2013; 8(10):e76002. PubMed ID: 24146808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.